Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.63
HZNP's Cash to Debt is ranked higher than
62% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. HZNP: 0.63 )
HZNP' s 10-Year Cash to Debt Range
Min: 0.22   Max: 2.13
Current: 0.63

0.22
2.13
Equity to Asset 0.48
HZNP's Equity to Asset is ranked higher than
59% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. HZNP: 0.48 )
HZNP' s 10-Year Equity to Asset Range
Min: -0.19   Max: 0.6
Current: 0.48

-0.19
0.6
F-Score: 4
Z-Score: 1.46
M-Score: 0.44
WACC vs ROIC
19.23%
12.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -2.86
HZNP's Operating margin (%) is ranked higher than
59% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. HZNP: -2.86 )
HZNP' s 10-Year Operating margin (%) Range
Min: -1841.5   Max: -2.86
Current: -2.86

-1841.5
-2.86
Net-margin (%) -88.77
HZNP's Net-margin (%) is ranked higher than
52% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. HZNP: -88.77 )
HZNP' s 10-Year Net-margin (%) Range
Min: -1635.12   Max: -88.77
Current: -88.77

-1635.12
-88.77
ROE (%) -159.17
HZNP's ROE (%) is ranked lower than
53% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. HZNP: -159.17 )
HZNP' s 10-Year ROE (%) Range
Min: -523.78   Max: -57.66
Current: -159.17

-523.78
-57.66
ROA (%) -41.98
HZNP's ROA (%) is ranked higher than
52% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. HZNP: -41.98 )
HZNP' s 10-Year ROA (%) Range
Min: -176.97   Max: -31.86
Current: -41.98

-176.97
-31.86
ROC (Joel Greenblatt) (%) -179.86
HZNP's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. HZNP: -179.86 )
HZNP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5030.52   Max: -154.09
Current: -179.86

-5030.52
-154.09
Revenue Growth (3Y)(%) 66.40
HZNP's Revenue Growth (3Y)(%) is ranked higher than
98% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. HZNP: 66.40 )
HZNP' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 66.4
Current: 66.4

0
66.4
EPS Growth (3Y)(%) -36.90
HZNP's EPS Growth (3Y)(%) is ranked higher than
56% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. HZNP: -36.90 )
HZNP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -36.9
Current: -36.9

» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

HZNP Guru Trades in Q1 2014

Paul Tudor Jones 16,733 sh (+14.25%)
Jim Simons Sold Out
» More
Q2 2014

HZNP Guru Trades in Q2 2014

Joel Greenblatt 57,769 sh (New)
Paul Tudor Jones Sold Out
» More
Q3 2014

HZNP Guru Trades in Q3 2014

Paul Tudor Jones 294,814 sh (New)
Steven Cohen 934,396 sh (New)
Joel Greenblatt 80,834 sh (+39.93%)
» More
Q4 2014

HZNP Guru Trades in Q4 2014

Steven Cohen 2,614,700 sh (+179.83%)
Joel Greenblatt 107,898 sh (+33.48%)
Paul Tudor Jones 274,577 sh (-6.86%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 9.20
HZNP's Forward P/E is ranked higher than
99% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. HZNP: 9.20 )
N/A
P/B 6.10
HZNP's P/B is ranked higher than
60% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. HZNP: 6.10 )
HZNP' s 10-Year P/B Range
Min: 0.8   Max: 14.89
Current: 6.1

0.8
14.89
P/S 7.40
HZNP's P/S is ranked higher than
56% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. HZNP: 7.40 )
HZNP' s 10-Year P/S Range
Min: 1.47   Max: 19.46
Current: 7.4

1.47
19.46
PFCF 93.00
HZNP's PFCF is ranked higher than
80% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1165.60 vs. HZNP: 93.00 )
HZNP' s 10-Year PFCF Range
Min: 45.11   Max: 433
Current: 93

45.11
433
POCF 66.09
HZNP's POCF is ranked higher than
72% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. HZNP: 66.09 )
HZNP' s 10-Year POCF Range
Min: 38.27   Max: 185.57
Current: 66.09

38.27
185.57
EV-to-EBIT -336.25
HZNP's EV-to-EBIT is ranked higher than
50% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. HZNP: -336.25 )
HZNP' s 10-Year EV-to-EBIT Range
Min: -325.1   Max: -0.1
Current: -336.25

-325.1
-0.1
Current Ratio 1.49
HZNP's Current Ratio is ranked higher than
60% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. HZNP: 1.49 )
HZNP' s 10-Year Current Ratio Range
Min: 0.29   Max: 3.17
Current: 1.49

0.29
3.17
Quick Ratio 1.41
HZNP's Quick Ratio is ranked higher than
67% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. HZNP: 1.41 )
HZNP' s 10-Year Quick Ratio Range
Min: 0.28   Max: 3
Current: 1.41

0.28
3
Days Inventory 63.08
HZNP's Days Inventory is ranked higher than
92% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. HZNP: 63.08 )
HZNP' s 10-Year Days Inventory Range
Min: 13.1   Max: 184.95
Current: 63.08

13.1
184.95
Days Sales Outstanding 90.85
HZNP's Days Sales Outstanding is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. HZNP: 90.85 )
HZNP' s 10-Year Days Sales Outstanding Range
Min: 67.08   Max: 124.99
Current: 90.85

67.08
124.99

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 30.00
HZNP's Price/DCF (Projected) is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. HZNP: 30.00 )
HZNP' s 10-Year Price/DCF (Projected) Range
Min: 14.99   Max: 14.99
Current: 30

Price/Median PS Value 1.60
HZNP's Price/Median PS Value is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. HZNP: 1.60 )
HZNP' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 1.46
Current: 1.6

0.39
1.46
Earnings Yield (Greenblatt) -0.30
HZNP's Earnings Yield (Greenblatt) is ranked higher than
61% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. HZNP: -0.30 )
HZNP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.1   Max: 0
Current: -0.3

-1.1
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 
Horizon Pharma plc to Host Fourth Quarter 2014 Conference Call and Webcast on February 27, 2015 Jan 28 2015 
Horizon Pharma plc Provides Business Update Jan 12 2015 
Horizon Pharma plc Files Patent Infringement Lawsuit Against Watson Laboratories, Inc. for Filing an Dec 24 2014 
Horizon Pharma plc to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014 
Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholder Nov 14 2014 
Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders Nov 13 2014 
Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Table Nov 12 2014 
Horizon Pharma plc Appoints John J. Kody as Executive Vice President and Chief Commercial Officer Nov 06 2014 
Horizon Pharma plc Announces DUEXIS(R) Selected as Winner of Chicago Innovation Award Oct 31 2014 


More From Other Websites
Window Dressing Hits Stocks In Final-Hour Sell-Off Mar 31 2015
3 Small Cap Pharma Stocks Set to Surge Following Q1 Earnings - Stocks in the News Mar 31 2015
Market set to notch ninth straight quarterly rise Mar 31 2015
Horizon Pharma Upgraded On 'Game Changer' Acquisition Mar 31 2015
Horizon Pharma to Buy Hyperion Therapeutics for $1.1B - Analyst Blog Mar 31 2015
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of HYPERION THERAPEUTICS INC. of... Mar 31 2015
The Bull Case: Supply & Demand Edition Mar 31 2015
Big Pharma Merger Monday Deals Disregard Biotech Bubble Talks Mar 31 2015
Top Analyst Upgrades and Downgrades: Brocade, IAC, Nabors, Priceline, Teva, Yamana Gold Mar 31 2015
Strength Seen in Horizon Pharma (HZNP): Stock Rises 18.2% - Tale of the Tape Mar 31 2015
HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 31 2015
Euro Slides on Greece as Oil Falls While Europe Stocks Pare Gain Mar 31 2015
Five Firms Take Lead in Health-Care Deal Flurry: Business of Law Mar 30 2015
Cramer Remix: In all my years, never seen this! Mar 30 2015
Stocks: Dow up 264, back in the black for '15 Mar 30 2015
Asian Futures Jump Amid Global Rally; Crude, Gold Decline Mar 30 2015
Horizon Pharma buying Hyperion for about $1.1 billion Mar 30 2015
Cramer: Two streams of money pouring into market Mar 30 2015
Teva, Horizon See Growth In Orphan-Drug Takeovers Mar 30 2015
WSJ Market Wrap: March 30, 2015 Mar 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK